Oral iron deficiency therapy
View Patent ↗Methods of normalizing iron levels, treating iron deficiency and disorders related thereto, such as anemia, as described. Pharmaceutical compositions effective for such treatments are also described.
1. A method of treating iron deficiency in a human patient comprising swallowing one or more immediate release solid oral dosage forms comprising a delivery agent and an iron compound, wherein the weight ratio of iron compound to the delivery agent is from about 2:1 to about 1:700, and wherein the delivery agent is selected from N-[8-(2-hydroxybenzoyl)amino]caprylic acid, N-(10-[2-hydroxybenzoyl]amino)decanoic acid, N-(8-[2-hydroxy-5-chlorobenzoyl]-amino)octanoic acid, 4-[(2-hydroxy-4-chloro-benzoyl)-amino]butanoic acid, 8-(2-hydroxyphenoxy)octyldiethanolamine, 8-(N-2-hydroxy-4-methoxybenzoyl)aminocaprylic acid, 3-toluoxybutanoic acid, and pharmaceutically salts thereof.
2. A method of treating anemia in a human patient comprising swallowing one or more solid oral dosage forms comprising a delivery agent and an iron compound, wherein the weight ratio of iron compound to the delivery agent is from about 2:1 to about 1:700, and wherein the delivery agent is selected from N-[8-(2-hydroxybenzoyl)amino]caprylic acid, N-(10-[2-hydroxybenzoyl]amino)decanoic acid, N-(8-[2-hydroxy-5-chlorobenzoyl]-amino) octanoic acid, 4-[(2-hydroxy-4-chloro-benzoyl)-amino]butanoic acid, 8-(2-hydroxyphenoxy) octyldiethanolamine, 8-(N-2-hydroxy-4-methoxybenzoyl)-aminocaprylic acid, 3-toluoxybutanoic acid, and pharmaceutically salts thereof.
3. The method of claim 1 , wherein the delivery agent is N-(8-[2-hydroxy-5-chlorobenzoyl]-amino)octanoic acid, or a pharmaceutically salt thereof.
4. The method of claim 1 , wherein the delivery agent is 3-toluoxybutanoic acid, or a pharmaceutically salt thereof.
5. The method of claim 1 , wherein the delivery agent is N-(10-[2-hydroxybenzoyl]amino)decanoic acid, or a pharmaceutically salt thereof.
6. The method of claim 1 , wherein the delivery agent is 4-[(2-hydroxy-4-chloro-benzoyl)-amino]butanoic acid, or a pharmaceutically salt thereof.
7. The method of claim 1 , wherein the delivery agent is 8-(2-hydroxyphenoxy)octyldiethanolamine, or a pharmaceutically salt thereof.
8. The method of claim 1 , wherein the delivery agent is 8-(N-2-hydroxy-4-methoxybenzoyl)-aminocaprylic acid, or a pharmaceutically salt thereof.
9. The method of claim 1 , wherein the human patient has chronic kidney disease.
10. The method of claim 1 , wherein the human patient is undergoing dialysis.
11. The method of claim 1 , wherein the human patient has Crohn's disease.
12. The method of claim 1 , wherein the human patient has cancer.
13. The method of claim 1 , wherein the human patient has gastritis or Celiac disease.
14. The method of claim 1 , wherein the dosage form is a tablet.
15. The method of claim 1 , wherein the delivery agent is a monosodium salt of N-[8-(2-hydroxybenzoyl)amino]caprylic acid.
16. The method of claim 1 , wherein the iron compound is ferrous sulfate, or a hydrate thereof.
17. The method of claim 1 , wherein the weight ratio of iron compound to the delivery agent is from about 1:2 to about 1:100.
18. The method of claim 1 , wherein the weight ratio of iron compound to the delivery agent is from about 1:3 to about 1:20.
19. The method of claim 1 , wherein the weight ratio of iron compound to the delivery agent is from about 1:4 to about 1:10.
20. The method of claim 2 , wherein the weight ratio of iron compound to the delivery agent is from about 1:2 to about 1:100.
21. The method of claim 2 , wherein the weight ratio of iron compound to the delivery agent is from about 1:3 to about 1:20.
22. The method of claim 2 , wherein the weight ratio of iron compound to the delivery agent is from about 1:4 to about 1:10.